SPONTANEOUS IMMUNOGLOBULIN-SYNTHESIZING ACTIVITY OF B LYMPHOCYTES IN INFLAMMATORY RHEUMATIC DISEASES

SPONTANEOUS IMMUNOGLOBULIN-SYNTHESIZING ACTIVITY OF B LYMPHOCYTES IN INFLAMMATORY RHEUMATIC DISEASES

Abstract. The aim of present work was to evaluate clinical significance of B-lymphocytes spontaneous antibody-synthesizing activity by B-lymphocytes (LASA) in patients with rheumatic inflammatory diseases (RD), i.e., reactive arthritis (ReA), ankylosing spondylitis (AS), rheumatoid arthritis (RA), a...

Full description

Bibliographic Details
Main Authors:	A.T. T. Mamasaidov, K. T. Ashirov, G. M. Mamasaidova, G. A. Kulchinova, D. I. Abdurashitova, M. Yu. Shakirov, A. P. Irissov, Ch. A. Eshbaeva, Z. B. Nurmamatov
Format:	Article
Language:	Russian
Published:	SPb RAACI 2014-07-01
Series:	Medicinskaâ Immunologiâ
Subjects:	reactive arthritis ankylosing spondylitis rheumatoid arthritis systemic lupus erythematosus rheumatic inflammatory diseases в-lymphocytes immunoglobulins
Online Access:	https://www.mimmun.ru/mimmun/article/view/235

Similar Items

Histopathology of the gut in rheumatic diseases
by: F. Macaluso, et al.
Published: (2018-10-01)

Temporomandibular joint dysfunction in various rheumatic diseases
by: F.J. Aceves-Avila, et al.
Published: (2013-07-01)

Spectrum of central nervous system involvement in rheumatic diseases: pictorial essay
by: Renata Mendes Vieira, et al.
Published: (2018-07-01)

The Role of Gamma Delta T Cells in Autoimmune Rheumatic Diseases
by: Ilan Bank
Published: (2020-02-01)

Systemic Inflammatory Response and Atherosclerosis: The Paradigm of Chronic Inflammatory Rheumatic Diseases
by: Aikaterini Arida, et al.
Published: (2018-06-01)

Cardiovascular safety of non-steroidal anti-inflammatory drugs in chronic inflammatory rheumatic diseases
by: B V Zavodovsky, et al.
Published: (2018-08-01)

Persistence and costs with subcutaneous TNF-alpha inhibitors in immune-mediated rheumatic disease stratified by treatment line
by: Svedbom A, et al.
Published: (2017-01-01)

Influence of age on the occurrence of adverse events in rheumatic patients at the onset of biological treatment: data from the BIOBADASER III register
by: Paloma Vela, et al.
Published: (2020-06-01)

Evaluation of the safety and satisfaction of rheumatic patients with accelerated infliximab infusion
by: Jozélio Freire de Carvalho, et al.
Published: (2018-08-01)

Intestinal microsporidiosis: a hidden risk in rheumatic disease patients undergoing anti-tumor necrosis factor therapy combined with disease-modifying anti-rheumatic drugs?
by: Nadia Emi Aikawa, et al.
Published: (2011-01-01)

SPONTANEOUS PROLIFERATIVE ACTIVITY OF B1LYMPHOCYTES IN RHEUMATOID ARTHRITIS, SYSTEMIC LUPUS ERYTHEMATOSUS AND NON1SPECIFIC ULCERATIVE COLITIS
by: A. Mamasaidov A.T., Mamasaidov, et al.
Published: (2014-07-01)

Th22 Cells Contribution in Immunopathogenesis of Rheumatic Diseases
by: Gholamreza Azizi, et al.
Published: (2015-10-01)

Characteristic of no-synthase of peripheral blood lymphocytes of patients with rheumatic pathology
by: Ulyana Efremova, et al.
Published: (2015-03-01)

Coexistence of rheumatoid arthritis and ankylosing spondylitis
by: Tacjana Anna Barczyńska, et al.
Published: (2015-12-01)

CONSERVATIVE ORTHOPEDIC TREATMENT OF RHEUMATIC DISEASES: RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS, OSTEOARTHROSIS, SOFT TISSUE DISEASES (PART II)
by: V P Pavlov
Published: (2009-06-01)

Cell-Free DNA as a Biomarker in Autoimmune Rheumatic Diseases
by: Bhargavi Duvvuri, et al.
Published: (2019-03-01)

Assessment of nutritional deficiency manifestations in patients with rheumatic diseases
by: Emad Elshebini, et al.
Published: (2021-04-01)

Association between use of disease-modifying antirheumatic drugs and diabetes in patients with ankylosing spondylitis, rheumatoid arthritis, or psoriasis/psoriatic arthritis: a nationwide, population-based cohort study of 84,989 patients
by: Chen HH, et al.
Published: (2017-05-01)

Body Mass Index and Disease Activity in Chronic Inflammatory Rheumatic Diseases: Results of the Cardiovascular in Rheumatology (Carma) Project
by: Jesús A. Valero-Jaimes, et al.
Published: (2021-01-01)

The troubling liaison between cancer and metabolic syndrome in chronic inflammatory rheumatic diseases
by: Giovanni Cioffi, et al.
Published: (2021-03-01)

Comorbidities in inflammatory joint and spine diseases in XXI century
by: I Z Gaydukova, et al.
Published: (2018-12-01)

Frequency of the use of biological treatment of patients with rheumatoid arthritis and ankylosing spondylitis in Lower Silesia
by: Wojciech Tański, et al.
Published: (2016-09-01)

TEMPOROMANDIBULAR JOINT INVOLVEMENT IN RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS: A CROSS-SECTIONAL STUDY
by: Cristina Iordache, et al.
Published: (2018-01-01)

THE FIRST EXPERIENCE IN USING ADALIMUMAB IN PATIENTS WITH ANKYLOSING SPONDYLITIS: CLINICAL AND MRICOMPARISONS OF THE RESULTS OF THERAPY
by: A G Bochkova, et al.
Published: (2010-02-01)

Treatment persistence of subcutaneous TNF inhibitors among Australian patients with immune-mediated rheumatic disease (IMRD)
by: Acar M, et al.
Published: (2018-11-01)

Bone phenotypes in rheumatology – there is more to bone than just bone
by: Christian S. Thudium, et al.
Published: (2020-11-01)

What is the Frequency of Internet Searches by Patients with Rheumatic Diseases? To What Degree are the Websites They Get Information from Reliable and What is the Effect of These Websites on Their Treatment?
by: Aysel Gürcan Atçı, et al.
Published: (2020-07-01)

IL-23/IL-17 INHIBITORS IN IMMUNOINFLAMMATORY RHEUMATIC DISEASES: NEW HORIZONS
by: E. L. Nasonov, et al.
Published: (2019-09-01)

Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study
by: Joshua L. Lee, et al.
Published: (2018-08-01)

IL-23 and Th17 Disease in Inflammatory Arthritis
by: Toru Yago, et al.
Published: (2017-08-01)

Persistence to subcutaneous biological agents in Hungarian patients treated for inflammatory arthritis
by: Takacs P, et al.
Published: (2019-01-01)

Association Between Nursing Support Levels and Effectiveness of Golimumab in the Management of Patients with Rheumatologic Diseases
by: Hermine Leroi, et al.
Published: (2020-05-01)

Serum heat-shock protein-65 antibody levels are elevated but not associated with disease activity in patients with rheumatoid arthritis and ankylosing spondylitis
by: Ulusoy H, et al.
Published: (2018-05-01)

Severe adverse events from treatment with genetically engineered biological agents in patients with rheumatic diseases
by: S V Moiseev, et al.
Published: (2013-05-01)

Sarcopenia in Patients with Rheumatic Diseases: Prevalence and Associated Risk Factors
by: Michele Barone, et al.
Published: (2018-12-01)

Effect of biologics in the level of cytokines in the synovial fluid of patients with ankylosing spondylitis
by: Bon San Koo, et al.
Published: (2020-03-01)

Distinctive Expression of Bone Metabolism-related Genes between PBMCs from Condylar Hyperplasia, Rheumatoid Arthritis, and Ankylosing Spondylitis Patients
by: Reza Amirzargar, et al.
Published: (2020-10-01)

Machine learning-based prediction model for responses of bDMARDs in patients with rheumatoid arthritis and ankylosing spondylitis
by: Seulkee Lee, et al.
Published: (2021-10-01)

Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?
by: M. Rossini, et al.
Published: (2015-03-01)

NEW POSSIBILITIES OF PHARMACOTHERAPY FOR IMMUNOINFLAMMATORY RHEUMATIC DISEASES: A FOCUS ON INHIBITORS OF INTERLEUKIN-17
by: E. L. Nasonov
Published: (2017-03-01)